Search

Early detection and effective treatment are crucial to reduce the physical, emotional, and financial pressure exerted by growing cancer burden on individuals, families, communities, and health systems. Currently, it is clear that the accurate analysis of emerging cancer epigenetic and metastatic-related biomarkers at different molecular levels is envisaged as an exceptional solution for early and reliable diagnosis and the improvement of therapy efficiency through personalized treatments. Within this field, electrochemical biosensing has demonstrated to be competitive over other emerging and currently used methodologies for the determination of these biomarkers accomplishing the premises of user-friendly, multiplexing ability, simplicity, reduced costs and decentralized analysis, demanded by clinical oncology, thus priming electrochemical biosensors to spark a diagnostic revolution for cancer prediction and eradication. This review article critically discusses the main characteristics, opportunities and versatility exhibited by electrochemical biosensing, through highlighting representative examples published during the last two years, for the reliable determination of these emerging biomarkers, with great diagnostic, predictive and prognostic potential. Special attention is paid on electrochemical affinity biosensors developed for the single or multiplexed determination of methylation events, non-coding RNAs, ctDNA features and metastasis-related protein biomarkers both in liquid and solid biopsies of cancer patients. The main challenges to which further work must be addressed and the impact of these advances should have in the clinical acceptance of these emerging biomarkers are also discussed which decisively will contribute to understand the molecular basis involved in the epigenetics and metastasis of cancer and to apply more efficient personalized therapies. Electrochemical biosensing to move forward in cancer epigenetics and metastasis. Image 1 • Accurate analysis of cancer epigenetic and metastatic-related biomarkers. • User-friendly, multiplexing ability, simplicity, reduced costs and decentralized analysis. • Opportunities and versatility exhibited by electrochemical biosensing in this field. • Representative examples published during the last two years. • Main challenges to solve and future impact and prospects. [ABSTRACT FROM AUTHOR]

Owing to the outstanding conductivity and biocompatibility as well as numerous other fascinating properties of two-dimensional (2D)-nanomaterials, 2D-based nanohybrids have shown unparalleled superiorities in the field of electrochemical biosensors. This review highlights latest advances in electrochemical immunosensors for clinical biomarkers based on different hybrid 2D-nanomaterials. Particular attention will be given to hybrid nanostructures involving graphene and other graphene-like 2D-layered nanomaterials (GLNs). Several recent strategies for using such 2D-nanomaterial heterostructures in the development of modern immunosensors, both for tagging or modifying electrode transducers, are summarized and discussed. These hybrid nanocomposites, quite superior than their rival materials, will undoubtedly have an important impact within the near future and not only in clinical areas. Current challenges and future perspectives in this rapidly growing field are also outlined. [ABSTRACT FROM AUTHOR]

The development of electrochemical magnetobiosensors for the simultaneous determination of two biomarkers associated with salivary oral cancer, protein IL-8 and its messenger RNA (IL-8 mRNA) associated, in undiluted human saliva samples is reported in this work. The implemented methodology involves the use of functionalized magnetic beads, specific antibodies against IL-8 protein, a specific hairpin DNA sequence for IL-8 mRNA and amperometric detection at disposable dual screen printed carbon electrodes. This methodology exhibits high sensitivity and selectivity for the target analytes providing detection limits of 0.21 nM for IL-8 mRNA and 72.4 pg mL −1 (far below the clinical established cut-off of 600 pg mL −1 ) for IL-8 protein in undiluted saliva samples. The dual amperometric magnetobiosensor was applied to the direct determination of both biomarkers in spiked raw saliva samples and to determine the endogenous content of IL-8 protein in saliva samples from 7 healthy individuals. The obtained results were statistically in agreement with those provided by a commercial ELISA kit. [ABSTRACT FROM AUTHOR]

A highly sensitive amperometric magnetoimmunosensor for the determination of ErbB2 protein, a well-known biomarker related to high-impact high-incidence diseases such as breast cancer, is described. A sandwich format involving the covalent immobilization of a specific capture antibody onto magnetic beads (MBs) and incubation of the modified MBs with a mixture solution of the antigen and a HRP-labeled detector antibody was used. The resulting modified MBs were captured on the surface of a disposable screen-printed carbon electrode (SPCE) and the amperometric responses at −0.20 V were measured. This ErbB2 magnetoimmunosensor exhibited a very low detection limit of 26 pg mL − 1 far below the established cut-off for this biomarker (15 ng mL −1 ) and was successfully applied to the quantitation of ErbB2 in human serum and cell lysates samples without any matrix effect. In addition, the developed assay allowed the assessment of ErbB2 status directly in intact breast cancer cells. The results correlated well with those obtained with a commercial ELISA method, thus demonstrating that the new magnetoimmunosensing platform offers a truthful and useful analytical tool to be easily applied in breast cancer diagnosis through either ErbB2 protein determination or breast cancer cell status detection. [ABSTRACT FROM AUTHOR]

An amperometric immunoassay for the determination of tumor necrosis factor alpha (TNFα) protein biomarker in human serum based on the use of magnetic microbeads (MBs) and disposable screen-printed carbon electrodes (SPCEs) has been developed. The specifically modified microbeads were magnetically captured on the working electrode surface and the amperometric responses were measured at -0.20 V (vs. Ag pseudo-reference electrode), upon addition of hydroquinone (HQ) as electron transfer mediator and H2O2 as the enzyme substrate. After a thorough optimization of the assay, extremely low limits of detection were achieved: 2.0 pg mL-1 (36 fM) and 5.8 pg mL-1 (105 fM) for standard solutions and spiked human serum, respectively. The simplicity, robustness and this clinically interesting LOD proved the developed TNFα immunoassay as a good contender for real clinical application. [ABSTRACT FROM AUTHOR]